Table 2.

Effects of topiramate on cognition in normal controls.

Study	Dose of TPM (mg/day)	n	Time on TPM (weeks)	Cognitive AEs from TPM
Martin et al. [1999]	5.7 mg/kg	TPM = 6	4	Psychomotor speed, verbal memory
		LTG = 5
		GBP = 6
Meador et al. [2005]	300	TPM = 37	8	Attention/vigilance, memory, naming and verbal fluency, cognitive/motor speed
		LTG = 38
Salinsky et al. [2005]	200–400	TPM = 15	12	Psychomotor speed, verbal contextual memory, consistency of word recall, letter fluency
		GBP = 16
		Placebo = 8
Werz et al. [2006]	300	TPM = 37	12	Attention/vigilance, and verbal memory, naming and verbal fluency, and psychomotor speed
		LTG = 37
		(cross-over)
Loring et al. [2011]*	64	76	24	Dose dependent, clinically significant deficits, beginning at the 96 mg/day dose. At highest dose, deficits in visual and verbal memory, naming, and reaction speed
	96	75
	192	76
	384	78
	Placebo	75

^*Cognitively normal obese population. AE, adverse event; GBP, gabapentin; LTG, lamotrigine; TPM, topiramate.